arrow
G

George A. Ward

astex pharmaceuticals
H指数:19
被引数:1,616

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

IAP antagonist tolinapant (ASTX660) in combination with pembrolizumab in advanced solid tumors: a phase I trial

IAP拮抗剂托利那潘特(ASTX660)联合帕博利珠单抗治疗晚期实体瘤:一项I期临床试验

2026-09-300
OA
Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy

肿瘤和基质区室中的坏死性凋亡决定了对免疫原性细胞死亡为基础的免疫治疗的反应性

2026-03-010
OA
Ubiquitylation of MLKL at lysine 219 positively regulates necroptosis-induced tissue injury and pathogen clearance
2021-06-0752
OAAI
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1H,2H,3H-pyrrolo[3,2-b]pyridin-1-yl)-2-[(2R,5R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)
2018-08-0942
PREAI
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
2017-06-01265
OAAI
Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP)
2017-05-2467
PREAI
Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP
2015-08-0794
PREAI